| Help | About | Contact Us

Publication : Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease.

First Author	Van de Veire S	Year	2010
Journal	Cell	Volume	141
Issue	1	Pages	178-90
PubMed ID	20371353	Mgi Jnum	J:160745
Mgi Id	MGI:4455062	Doi	10.1016/j.cell.2010.02.039
Citation	Van de Veire S, et al. (2010) Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease. Cell 141(1):178-90

abstractText

Our findings that PlGF is a cancer target and anti-PlGF is useful for anticancer treatment have been challenged by Bais et al. Here we take advantage of carcinogen-induced and transgenic tumor models as well as ocular neovascularization to report further evidence in support of our original findings of PlGF as a promising target for anticancer therapies. We present evidence for the efficacy of additional anti-PlGF antibodies and their ability to phenocopy genetic deficiency or silencing of PlGF in cancer and ocular disease but also show that not all anti-PlGF antibodies are effective. We also provide additional evidence for the specificity of our anti-PlGF antibody and experiments to suggest that anti-PlGF treatment will not be effective for all tumors and why. Further, we show that PlGF blockage inhibits vessel abnormalization rather than density in certain tumors while enhancing VEGF-targeted inhibition in ocular disease. Our findings warrant further testing of anti-PlGF therapies.

Your name:
Your email address:
Subject:
Message:	---- Current page: ---- /mousemine/report.do?id=74246907&trail=%7C74246907

MouseMine

Publication : Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease.

External Links

Expression

Publication --> Expression annotations

Other

51 Authors

9 Bio Entities

0 Expression